American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

CDC data highlights surge in obesity rates, driving demand for weight loss drugs

by admin September 13, 2024
September 13, 2024
CDC data highlights surge in obesity rates, driving demand for weight loss drugs

Recent data from the Centers for Disease Control and Prevention (CDC) underscores a dramatic shift in obesity trends across the US over the past decade.

The 2023 figures highlight a persistent and widespread obesity crisis, bolstering the market for weight loss drugs, where Eli Lilly and Novo Nordisk are currently the leading players.

Key findings from the CDC data

The CDC’s latest report reveals that every US state now has at least 20% of its adult population classified as obese.

Notably, 23 states have an obesity prevalence exceeding 35%, indicating that one in three adults in these regions could benefit from weight loss treatments.

Obesity is often linked to factors beyond diet, and the CDC emphasizes the urgent need for advanced treatment options.

According to Karen Hacker of the CDC, this data underscores the critical demand for effective obesity prevention and treatment strategies.

In response to the growing need, Novo Nordisk and Eli Lilly have emerged as leaders in the weight loss drug market.

Novo Nordisk’s Wegovy, a GLP-1 receptor agonist, and Eli Lilly’s Zepbound have been particularly successful.

Both companies have seen substantial revenue increases over the past year due to the high demand for their weight loss solutions.

Novo Nordisk vs. Eli Lilly

Novo Nordisk is expanding its portfolio with amycretin, a new drug that combines two peptide hormones in a single molecule.

This innovative approach aims to enhance appetite regulation and hunger control, offering a potential alternative to Wegovy.

In response to the high demand and supply constraints, Eli Lilly is investing $1.8 billion to boost its production capabilities for weight loss, Alzheimer’s, and diabetes medications.

The company is focusing on expanding its Kinsale, Ireland facility, with an additional $800 million investment to increase its manufacturing capacity.

UBS now expects the weight loss drug market to grow at a compound annualized rate of 33% and hit $150 billion in sales by 2029 – up from the firm’s earlier forecast of about $125 billion. 

The company has also achieved a major milestone by securing regulatory approval for its weight management drug, Mounjaro, in China. 

Novo Nordisk has also got approval for its weight-loss drug from China.

Both Novo Nordisk and Eli Lilly are well-positioned to capitalize on the ongoing obesity trend.

Despite current short-term supply issues potentially impacting stock performance, the long-term outlook for these companies remains strong.

Their advancements and expansions in the weight loss sector suggest promising medium-term investment opportunities.

The post CDC data highlights surge in obesity rates, driving demand for weight loss drugs appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Are Lloyds Bank, NatWest, and Barclays at risk from Revolut?
next post
Is Rivian truly ‘one or two programs away from bankruptcy’?

Related Posts

Nike shares jump on improved outlook, shift from...

June 27, 2025

Asian markets open: Nikkei drops 1.33%; Sensex pre-open...

June 13, 2025

Michael Burry loads up on Alibaba stock: should...

November 16, 2024

Ethereum drops 7% below $4,200 amid liquidations, rising...

September 22, 2025

Opendoor stock plunges 21% after weak forecast: could...

August 7, 2025

How this small-cap Indian stock surged more than...

January 27, 2025

S&P 500 slips as economic uncertainty weighs on...

March 21, 2025

Europe market opens in green: STOXX 600 rallies...

September 23, 2025

Here’s a Trump trade that hasn’t played out...

January 27, 2025

Joel Kaplan: meet Meta’s newly appointed chief global...

January 3, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Bulgaria plans for continuous oil supply for Lukoil-owned refinery after US sanctions

      October 26, 2025
    • Apple Q4 earnings preview: here’s what to expect

      October 26, 2025
    • France’s offshore wind ambitions stalled by political turmoil

      October 26, 2025
    • Europe bulletin: Zelensky calls for more weapons, Russia warns against EU sanctions

      October 26, 2025
    • US digest: Jeffries endorses Mamdani, Ford’s stock surge, US sanctions Colombian president

      October 26, 2025

    Categories

    • Business (4,373)
    • Investing (3,014)
    • Latest News (2,103)
    • Politics (1,541)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved